This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Ebenbuild Gmbh. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Karl-Robert Klaus Wichmann: Innovator in Pulmonary Drug Delivery
Introduction
Karl-Robert Klaus Wichmann is a notable inventor based in Munich, Germany. He has made significant contributions to the field of pulmonary drug delivery through his innovative methods and systems. His work focuses on enhancing the efficacy of aerosol delivery systems, which are crucial for effective medication administration.
Latest Patents
Wichmann holds a patent for a "Method for assessing the efficacy of an aerosol for pulmonary drug delivery as well as inhaler device, orally inhaled and/or nasal drug product and drug/device combination product." This invention relates to systems and methods for evaluating the effectiveness of aerosols used in pulmonary drug delivery. The patent outlines a process that includes providing a computational lung model and a particle transport and deposition model. It computes the spatial particle deposition distribution of discrete particles and assesses the efficacy of the aerosol based on this distribution.
Career Highlights
Wichmann is associated with Ebenbuild GmbH, where he applies his expertise in developing advanced inhalation devices and drug delivery systems. His innovative approach has positioned him as a key figure in the field of respiratory therapeutics. His work is instrumental in improving patient outcomes through more effective drug delivery methods.
Collaborations
Wichmann collaborates with talented individuals such as Jonas Biehler and Kei Wieland Müller. These partnerships enhance the research and development efforts at Ebenbuild GmbH, fostering innovation in the field of pulmonary drug delivery.
Conclusion
Karl-Robert Klaus Wichmann's contributions to the field of pulmonary drug delivery are significant and impactful. His innovative methods and collaborations continue to advance the effectiveness of aerosol therapies, ultimately benefiting patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile